



EVITRADE SCIENTIST LEADS DISCUSSIONS ON CANNABIS EDUCATION

VANCOUVER, BC, Friday April 12, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF). Dr. Ricardo E Rivera-Acevedo member of EViTRADE’s scientific advisory board and renowned cannabinologist is leading the way for cannabis education in Canada.

In a recent article published in El Nuevo Día, one of Puerto Rico’s most important newspapers, Dr. Ricardo-Acevedo discussed his passion for cannabis science and his support for the education of the general public. “One of my goals is to educate the people about the health benefits of the cannabis plant and the important role that our research will play in a greater understanding of how we treat and use this plant for the betterment of our health” commented Dr. Rivera-Acevedo.

Dr. Rivera-Acevedo is an Adjunct Professor in the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia in Vancouver and consultant for various pharmaceutical companies around the world. In his spare time, he co-hosts the Cannabis Science Podcast and El Bus De Las 7 radio show on Vancouver Coop Radio 100.5 FM CFRO (<http://cannabisconciencia.org>).

Dr. Rivera-Acevedo’s accomplishments also include playing key roles in establishing the first clinical trial on the use of cannabis to combat acute pain in conjunction with the Fundación de Investigación (FDI Clinical Research) and the creation of a laboratory for the investigation of cannabis and cannabinoids within the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia.

EviTrade continues to work toward developing CBD protocols and research that integrate with the mission of elevating the human condition through advanced medical solutions and effective health and wellness products.

Contact:

EVITRADE Health Systems Corp.
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com or ceo@auxellence.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)

EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation), is a technology company specializing in the Health and Life Sciences sector looking to deliver effective personalized health solutions with a higher degree of predictability and consistency.

The Company is focused on the following areas to help improve health: personalized medical care (including CBD usage monitoring and effects on the cardiovascular system), molecular biology, nutraceutical solutions and genetic tailoring.

Through its subsidiaries' focus on technologies involved in extracting and purifying CBD extracts for its personalized healthcare system, the Company may be the first to offer a complete quality assured vertically integrated "CBD Health System" for monitoring and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.